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Objectives: Extracorporeal circulation is associated with the systemic inflammatory response syndrome. The ob-
jective of this study was to measure plasma and myocardial matrix metalloproteinase 2 and 9 levels in patients
undergoing off-pump coronary artery bypass and coronary artery bypass grafting.
Methods: Twenty patients subjected to coronary artery bypass grafting and 20 subjected to off-pump coronary
artery bypass surgery were included in this study. In both procedures blood was collected in 7 equivalent time
points up to 12 hours after grafting. The myocardial biopsy specimens were collected before and after extracor-
poreal circulation in the coronary artery bypass grafting group and after harvesting and completion of proximal
anastomoses in the off-pump coronary artery bypass group. Matrix metalloproteinase levels were measured by
means of zymography. Myeloperoxidase and tissue inhibitor of metalloproteinase 1 and 2 levels were measured
with an enzyme-linked immunosorbent assay.
Results: Coronary artery bypass grafting but not off-pump coronary artery bypass led to a 700- to 900-fold in-
crease of plasma matrix metalloproteinase 9 levels. A small but significant increase in matrix metalloproteinase
2 levels was detected in both procedures. Myocardial matrix metalloproteinase 9 levels significantly increased
at the end of coronary artery bypass grafting and off-pump coronary artery bypass. Increased matrix metallopro-
teinase 9 activity at the end of extracorporeal circulation was accompanied by augmentation of the endogenous
matrix metalloproteinase inhibitors tissue inhibitor of metalloproteinase 1 and 2 in plasma, but its magnitude
was unable to balance the plasma matrix metalloproteinase 9 increase. The matrix metalloproteinase 9 content
in plasma at the end of extracorporeal circulation correlated with the myeloperoxidase plasma concentration
(r2 ¼ 0.8212, P<0.05).
Conclusion:We propose that release of matrix metalloproteinase 9 might contribute to the extracorporeal circu-
lation–induced inflammatory reactions.
Cardiopulmonary Support Sokal et alSurgical coronary revascularization improves survival and
quality of life and attenuates a number of cardiac-related
hospitalizations in patients with coronary artery disease.1
However, extracorporeal circulation (ECC) used during cor-
onary artery bypass grafting (CABG) alters the structural
and functional properties of circulating cells, including
blood platelets and leukocytes, thus initiating their activation
and promoting the generalized systemic inflammation re-
sponse syndrome (SIRS).2,3 SIRS might cause severe post-
operative complications, such as neurologic, renal, and
pulmonary dysfunction, compromising the clinical outcome
of coronary revascularization. Moreover, reperfusion after
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injury, and this might contribute to myocardial stunning.
Off-pump coronary artery bypass (OPCAB) has been intro-
duced as an alternative to conventional ECC-supported
myocardial revascularization. The absence of ECC is
thought to markedly reduce proinflammatory cytokine re-
lease, thus limiting the incidence of SIRS and SIRS-related
postoperative complications.4
Matrix metalloproteinases (MMPs) are a family of zinc-
and calcium-dependent endopeptidases responsible for the
metabolism of extracellular matrix of the connective tissue.5
These proteinases play an important role in physiologic (eg,
growth and development) and pathologic (eg, inflammation
and cancer) processes. Of special interest for myocardial
function are MMP-2 and MMP-9, which have been identi-
fied in cardiomyocytes.6 MMP-2 and MMP-9 are over-
expressed in ventricular remodeling, aortic aneurysm
formation, and atherosclerosis plague rupture and might
contribute to the pathogenesis of these pathologies.7,8 The
expression and release ofMMPs is induced by proinflamma-
tory cytokines, including tumor necrosis factor a9 and inter-
leukin (IL) 1, IL-6, IL-8, and IL-10.10 Interestingly, MMPs
augment and modulate the inflammatory response through
effects on cytokine release and leukocyte extravasation.urgery c May 2009




CABG ¼ coronary artery bypass grafting
ECC ¼ extracorporeal circulation
IL ¼ interleukin
LVEF ¼ left ventricular ejection fraction
MMP ¼ matrix metalloproteinase
OPCAB ¼ off-pump coronary artery bypass
SIRS ¼ systemic inflammation response
syndrome
TIMP ¼ tissue inhibitor of metalloproteinase
The changes inMMP-2 andMMP-9 levels in plasma and tis-
sues have already been documented in patients undergoing
CABG.11,12 However, to our knowledge, the release of these
proteinases in patients undergoing OPCAB has not been
described. Therefore we have studied the time course of
plasma and myocardial levels of MMP-2 and MMP-9 in
patients undergoing CABG and OPCAB.
MATERIALS AND METHODS
Patient Selection and Description
Patients (n ¼ 40, 29 men and 11 women) with an average age of 62 
9.61 years undergoing elective coronary artery revascularization were en-
rolled in the study. Patients were enrolled after obtaining informed consent.
This protocol was reviewed and approved by the Institutional Review Board
of the Silesian Medical University in Katowice, Poland.
Patients with recent (<30 days) myocardial infarction, very low left ven-
tricular ejection fraction (LVEF;<30%), concomitant valvular or aortic dis-
ease, chronic or recent steroid therapy, chronic renal failure, malignancies,
autoimmunologic disease, ongoing or recent (<30 days) infection, and leu-
kocytosis (>10 3 109/L) were excluded from the study. We have also ex-
cluded patients with preoperative platelet dysfunction, as determined by
means of aggregometry.
Patients with multivessel coronary disease and a left ventricular ejection
of greater than 30% were included if they were deemed equally treatable
with CABG and OPCAB technique by means of consensus of cardiac
surgeon base of coronary angiographic analysis. The allocation of patients
between 2 groups (group 1, CABG; group 2, OPCAB) was based on the
institutional policy of the Silesian Centre for Heart Diseases. The policy
requires surgeons to perform the off-pump procedure in all cases of appro-
priate coronary anatomy. The final decision regarding surgical technique (ie,
CABG or OPCAB) has been made after intraoperative evaluation of the
coronary bed. For example, in case of an intramuscular course of the vessel,
the CABG technique was preferable. Operating surgeons were experienced
in both CABG and OPCAB procedures, as evidenced by a track record of
more than 100 operations for each procedure.
Sample Collection
Samples of blood were drawn from the radial arterial monitoring line in
standardized time points. In the CABGgroup these were as follows: A, before
induction of anesthesia (baseline); B, before initiation ofECC;C, immediately
after aortic crossclamp removal; D, immediately after cessation of ECC; E, at
30 minutes; F, at 6 hours; and G, at 12 hours after separation from ECC.
Time points in the OPCAB group were selected to correspond to those of
CABG as follows: A, before induction of anesthesia (baseline); B, after left
internal thoracic artery harvest; C, after completion of all distal anastomo-
ses; D, after completion of all proximal anastomoses; E, at 30 minutes; F,The Journal of Thoracic and Cat 6 hours; and G, at 12 hours after completion of all anastomoses. All sam-
ples were placed in ethylenediamine tetraacetic acid tubes and centrifuged
(2000g for 15 minutes at room temperature), and plasma was stored at
70C until assayed for the presence of MMP-2 and MMP-9.
Right auricular biopsy specimens were obtained in all patients at selected
time points. In the CABG group these were (1) just before ECC initiation
and (2) immediately after cessation of ECC. In the OPCAB group these
were (1) before graft implantation and (2) after completion of all graft im-
plantations. Biopsy samples were immediately frozen and stored at70C
until assayed for MMP-2 and MMP-9.
Mean duration of both CABG and OPCAB procedures, as well as biopsy
times, are shown in Table 1.
Sample Preparation and Analysis
Frozen tissue samples were crushed with a pestle and mortar at70C
and subsequently sonicated on ice in homogenization buffer. The samples
were then centrifuged at 2000g for 10 minutes at 4C, and the resultant su-
pernatant was used for the measurement of MMPs. Plasma samples were
subjected to zymographic analysis directly after thawing.
MMP-2 and MMP-9 levels were measured by means of gelatin
zymography under nonreducing conditions, as described before.13,14
Briefly, samples (20 mg of protein each) were subjected to 8% sodium
dodecylsulfate–polyacrylamide gel electrophoresis with copolymerized
2 mg/mL gelatin as a substrate. After electrophoresis, gels were renaturated
and stained with Coomassie Brilliant Blue. Both MMP-9 and MMP-2 were
identified by means of gelatinolysis, their molecular weight in comparison
with cellular (HT-1080 fibrosarcoma conditioned medium, ST1) and
recombinant (ST2) MMP standards (Figure 1, C and D), and inhibition
with selective MMP inhibitors. The abundance of MMPs in plasma and
myocardium was measured with the Gel Doc XR System (Bio-Rad Labora-
tories, Hercules, Calif) from calibration curves with regression analyses that
were constructed by using recombinant standards.15 Plasma MMP-2 and
MMP-9 were expressed in nanograms per milliliter, whereas myocardial
MMPs were expressed in nanograms per milligram of protein.
The immunoreactivity of tissue inhibitor of metalloproteinase (TIMP) 1,
TIMP-2, and myeloperoxidase (MPO; a specific granulocyte activity
marker) were measured in plasma by using a commercially available en-
zyme-linked immunosorbent assay (R&D systems, Minneapolis, Minn),
according to the manufacturer’s instructions.
Statistics
Results were expressed as the mean standard deviation for 20 separate
measurements. Comparisons were made with the Student’s t test for para-
metric data and the Mann–Whitney test for nonparametric data.
RESULTS
Table 2 shows some clinical characteristics of patients
undergoing CABG and OPCAB. There were no significant
differences in demographics and comorbidities in patients
enrolled in both the OPCAB and CABG groups. Clinical
and laboratory parameters, such as LVEF, New York Heat
Association class, Canadian Cardiovascular Society grade,
and red blood cell and platelet counts did not differ between
the investigated groups of patients. Of note, the mean white
blood cell count was higher in the OPCAB group than in the
CABG group (7.27 3 103/mL vs 6.47 3 103/mL, P< .05).
It is noteworthy that mortality/morbidity risk calculated
according to EuroSCORE classification was similar in the
CABG and OPCAB groups (2.85 vs 3.85, P ¼ .11). How-
ever, OPCAB resulted in less complete revascularization,ardiovascular Surgery c Volume 137, Number 5 1219
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STABLE 1. Mean duration of surgical intervention and time lapse to biopsy and blood sample collection (in minutes)






specimen no. 2 A B C D E F G
CABG 241  74.8 87.2  45.8 181  72.7 0 76.6  33.5 156  43.3 193  63.3 224  48.1 557  135 911  344
OPCAB 180  40.3 65.3  21.6 138  33.9 0 57  13.9 120  33.4 135  38.7 165  40.7 488  119 848  195
P value .003 .03 .0027 .02 .005 .0002 .0002 .0001 .0004
CABG, Coronary artery bypass grafting; OPCAB, off-pump coronary artery bypass.with a smaller number of coronary anastomoses (2.1 vs
2.75, P ¼ .01).
Time Course of Plasma and Myocardial MMP-9
PlasmaMMP-9 concentrations measured at the beginning
of surgical intervention (baseline, time point A) were similar
in both groups. At time point C, a significant increase in
plasma MMP-9 levels was only noted in the CABG group.
At time point D, MMP-9 concentrations in this group of pa-
tients were increased by 700- to 900-fold. In contrast, in the
OPCAB group MMP-9 concentrations in plasma remained
unaltered throughout the operation. However, a slight
increase was observed 6 hours after the completion of coro-
nary anastomoses (Figure 1, A).1220 The Journal of Thoracic and Cardiovascular SuThe myocardial MMP-9 level was significantly increased
at the end of surgical revascularization in both groups (Fig-
ure 2, A). No significant differences were found between the
2 groups.
Time Course of Plasma and Myocardial MMP-2
The concentrations of MMP-2 in the plasma of both the
CABG and OPCAB groups were unaltered during the oper-
ation. However, a small but significant increase in plasma
MMP-2 levels in both groups was detected 12 hours after
the operation (Figure 1, B).
The myocardial MMP-2 level in myocardium in both
groups was significantly increased after surgical intervention
(Figure 2, B).FIGURE 1. Top, Plasma gelatinase concentrations during coronary artery bypass grafting (CABG; A) and off-pump coronary artery bypass (OPCAB; B)
determined by means of quantitative zymographic analysis (see the Materials and Methods section). CABG resulted in great release of matrix metallopro-
teinase (MMP) 9, an effect not detected during OPCAB. Both CABG and OPCAB led to small increases in MMP-2 levels, and this effect was statistically
significant after surgical intervention. Data points are means  standard deviation (n ¼ 20). Bottom, Representative zymograms of patients with CABG (C)
and OPCAB (D): ST1 and ST2 standards.rgery c May 2009
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Because the activity ofMMP-9 is inhibited by endogenous
TIMP-1 and TIMP-2, the time course of plasma concentra-
tions of these inhibitors was also measured (Figure 3). Con-
centrations of TIMP-1 were maximally increased at time
point F by approximately 2.7-fold and approximately 1.7-
fold for the CABG and OPCAB groups, respectively.
TABLE 2. Clinical characteristics of study groups
CABG (n ¼ 20) OPCAB (n ¼ 20) P value
Mean age (y) 61.5  8.32 62.6  10.91 NS
Male/female sex 19/1 16/4 NS
Hypertension, n 20 (100%) 15 (75%) NS
Hypercholesterolemia, n 11 (55%) 10 (50%) NS
Diabetes mellitus, n 4 (20%) 4 (20%) NS
History of smoking, n 7 (35%) 10 (50%) NS
Obesity (BMI>30), n 12 (60%) 15 (75%) NS
NYHA class 1.25  0.44 1.55  0.69 NS
CCS grade 2.55  011 2.3  0.57 NS
LVEF (%) 45.40  9.8 45.25  8.9 NS
EuroSCORE 2.85  1.55 3.85  2.3 NS
No. of grafts 2.75  0.55 2.10  0.85 .01
CABG, Coronary artery bypass grafting; OPCAB, off-pump coronary artery bypass;
NS, not significant; BMI, body mass index; NYHA, New York Heart Association;
CCS, Canadian Cardiovascular Society; LVEF, left ventricular ejection fraction.The Journal of Thoracic and CIn contrast, concentrations of TIMP-2 were maximally in-
creased at time point D by approximately 3.8-fold for theOP-
CABgroup and approximately 5.9-fold for the CABGgroup.
Because both TIMP-1 and TIMP-2 bind to gelatinases
with a stechiometric ratio of 1:1 with similar affinity, we cal-
culated the cumulative concentration of TIMPs in plasma at
every time point. The maximal increase in total TIMP-1 and
TIMP-2 concentrations in plasma at the time of maximal
MMP-9 and MMP-2 release was only approximately 2.1-
fold higher than the basic level for the OPCAB group and
approximately 2.8-fold higher for the CABG group. Thus
the MMP-9 increase (700- to 900-fold) during the CABG
procedure could not be counterbalanced by similar increase
of TIMP concentrations.
Plasma MPO
A specific marker of neutrophil activation, MPO, was
measured at point D, corresponding to the maximal MMP-9
release. The MPO levels were significantly higher in the
CABG group than in the OPCAB group (Figure 4, A). More-
over, in the CABG group there was a significant correlation
(r2¼ 0.82, P<.005) betweenMPO andMMP-9 levels at the
time of the maximal release of MMP-9 (Figure 4, B). No sig-
nificant correlation was observed in the OPCAB group.C
P
SFIGURE 2. Myocardial gelatinase levels during coronary artery bypass grafting (CABG) and off-pump coronary artery bypass (OPCAB). The levels of ma-
trix metalloproteinase (MMP) 9 (A), but not MMP-2 (B), were increased during both types of operation. Bar graphs show mean values  standard deviation
(n ¼ 20).ardiovascular Surgery c Volume 137, Number 5 1221




Several authors have reported an increase in MMP levels
in plasma and heart tissue during cardiac surgery9,11,12,14,16
or after experimentally induced heart ischemia in animal
models.17,18 Some of these reports evidenced increased
MMP/TIMP ratios that led to increased inflammatory re-
sponses unopposed by inhibitor actions of MMPs.9,12,16,17
Interestingly, most of the studies that focused on the mea-
surement of MMPs during the ECC procedure assumed
(without any experimental confirmation) that observed
changes in MMP activity were caused by ECC but not by
the surgical procedure itself. For example, Lin and col-
leagues16 measured MMP-9 plasma concentrations using
enzyme-linked immunosorbent assays in 16 patients under-
going CABG and 5 patients undergoing OPCAB. They ob-
served no change in MMP-9 concentrations during the
OPCAB procedure. The highest MMP-9 increase (approxi-
mately 2.5-fold) was observed 4 hours after the beginning of
CABG. In contrast, Lalu and associates12 reported an almost
100-fold increase of MMP-9 activity directly after ECC dis-
continuation compared with the baseline concentration mea-
sured in samples collected shortly after initiation of ECC but
before ischemia. The current work has been designed to ad-
dress a number of outstanding questions related to interac-
tions between gelatinases (MMP-2 and MMP-9), ECC,
and cardiac surgery.
FIGURE 3. Changes in plasma tissue inhibitor of metalloproteinase
(TIMP) 1 (A) and TIMP-2 (B) concentrations during coronary artery bypass
grafting (CABG) and off-pump coronary artery bypass (OPCAB). Data
points are means  standard deviation (n ¼ 20).1222 The Journal of Thoracic and Cardiovascular SFirst, are both gelatinases increased during CABG and
OPCAB? This is a very pertinent problem because the 2 en-
zymes, although belonging to the same family of MMPs,
have different biologic profiles in their interactions with the
vasculature and platelets.19 Second, is the presence of ECC
responsible for the systemic release of gelatinases, or are
they released in response to surgical manipulations? Third,
can MMP upregulation be effectively opposed by the con-
comitant increase in TIMPs? Finally, what is the likely cellu-
lar source of MMPs released during cardiac surgery?
To address these questions, we compared tissue and
plasma levels of MMP-2 andMMP-9 at different time points
of CABG and OPCAB. Moreover, we measured plasma
concentrations of TIMP-1 and TIMP-2 to assess the func-
tional importance of observed changes in the activity of
MMPs. Finally, we assayed MPO levels to evaluate whether
neutrophil activation with associated release of gelatinase
granules could be held accountable for the release of
MMP-2, MMP-9, or both.
The most striking finding obtained in this study was the
response of MMP-9 to ECC. In less than 2 hours after initi-
ation of EEC, plasma levels of MMP-9 were increased by
700- to 900-fold. Furthermore, the rapid clearance (within
6 hours) of enzyme from the circulation coincided with the
cessation of ECC. In contrast, in patients undergoing OP-
CAB, the levels of MMP-9 remained unchanged during
the operation, indicating that the systemic MMP-9 release
FIGURE 4. A, Comparison of myeloperoxidase (MPO) concentrations in
plasma in the coronary artery bypass grafting (CABG) and off-pump coro-
nary artery bypass (OPCAB) groups at the point of maximal matrix metal-
loproteinase (MMP) 9 release. Data points are means  standard deviation
(n ¼ 20). B, Correlation plot between MPO and MMP-9 concentrations in
plasma in the CABG group at the point of maximal MMP-9 release.urgery c May 2009
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cedure itself. Interestingly, MMP-2 levels do not appear to
increase in a significant way during ECC, and its levels
are only moderately increased after discontinuation of
ECC in the early postoperative period.
What might be the biologic and clinical significance of
this dramatic increase of MMP-9? For a short period (<6
hours) after its release, the biologic effects of MMP-9 are
likely to be unopposed because the concomitant stimulation
of TIMPs (several fold increase) is not strong enough to
counteract a several-hundred-fold increase inMMP-9 levels.
However, the biologic consequences of even a short-lasting
increment in MMP-9 levels can be of importance because
the enzyme has been shown to acutely inhibit platelet aggre-
gation and play a central role in relaxin-mediated vasorelax-
ation.20-22 There is also evidence that a short-term increase
in MMP-9 levels could have important repercussion for car-
diac ischemia. Recently, Kelly and colleagues23 showed that
maximal MMP-9 increase in the first 20 hours of myocardial
infarction had an independent predictive value for lower
LVEF during admission and for greater change in left ven-
tricular end-diastolic volume between admission and fol-
low-up. These findings seem to confirm the previous
results of Lalu and colleagues,12 who showed negative cor-
relation between myocardial MMP-9 and MMP-2 activity
and left ventricular mechanical function. However, the effect
of increased MMP-9 concentrations during CABG on late
postoperative cardiac function requires further investigation.
What about long-lasting effects of systemic increase of
MMP-9 levels in other organs? ECC has been shown to gen-
erate a myriad of neuropsychologic and neuropsychiatric de-
viations that might last years after the exposure of patients to
ECC.24,25 This impairment is accompanied by the release of
neurobiochemical markers of brain damage (protein S-100B
and neuron-specific enolase).26 Many different mechanisms
underlying the phenomenon were proposed, including mi-
croembolization and inadequate cerebral flow.24,27 There
is substantial evidence linking blood–brain barrier failure
during cerebral ischemia to MMPs.28-32 We have found
that myocardial MMP-9 and MMP-2 levels increased post-
operatively to a similar extent during both CABG and OP-
CAB, indicating that this effect is caused predominantly
by intraoperative trauma/ischemia and might not be caused
by ECC. Interestingly, Cheung and coworkers18 have
shown, in an ex vivo model of an isolated working rat heart,
that ischemia and reperfusion lead to release ofMMP-2 from
cardiac muscle and that MMP-2 contributes to cardiac me-
chanical dysfunction, an effect dependent on degradation
of the myosin light chain.33 Whether a cardiac surgery–in-
duced increase in myocardial gelatinases affects myocardial
performance remains to be demonstrated.
The synthesis and secretion of MMPs by several cells can
be stimulated by different growth factors and cytokines, in-
cluding IL-1a and IL-1b, tumor necrosis factor a, transform-The Journal of Thoracic and Cing growth factor a, basic fibroblast growth factor, and
others.34,35 Interestingly, some of these mediators can rap-
idly cause an even 50-fold increase in MMP mRNA levels.
However, the MMP protein synthesis process is a longer-
lasting one, and therefore increased MMP release is not
observed until a few hours after stimulation. In our study
a significant increase in MMP-9 activity in plasma was
observed at point C and a maximal increase was seen at point
D (approximately 156 and 193 min after the beginning of the
procedure or approximately 79 and 116 minutes after ECC
initiation, respectively; Table 1). In contrast to the de novo
protein synthesis, the release ofMMP-9 bymeans of degran-
ulation of gelatinase granules is a fast event in neutrophils
and occurs within less than 1 hour when these cells are stim-
ulated with chemotactic factors, including the major neutro-
phil chemokine IL-8. This again contrasts with the de novo
synthesis of gelatinase B by monocytes, which is at least 10-
fold slower.36 A specific marker of neutrophil degranulation,
MPO, was measured in plasma samples to ascertain whether
leukocyte degranulation took place during the time ofMMP-
9 release. As expected, MPO levels were significantly higher
in the CABG group than in the OPCAB group at the point of
maximal MMP-9 release. Moreover, MPO levels closely
correlated with MMP-9 levels (r2 ¼ 0.82, P< 0.005). In
contrast, no significant correlation was observed in the OP-
CAB group. Therefore we propose thatMMP-9 was released
from leukocyte gelatinase granules as a result of ECC-indu-
ced cellular injury. However, we cannot definitely exclude
the possibility that MMP-9 increases were caused not by
ECC but by ischemic cardiac arrest.
In conclusion, we have found that MMP-9 is differentially
released to the systemic circulation during CABG and OP-
CAB surgery. However, surgical manipulations of myocar-
dium result in local upregulation of this enzyme. Therefore
we propose that the release of MMP-9 might contribute to
ECC-induced inflammatory reactions.
Finally, despite very similar characteristic of both studied
groups, it needs to be acknowledged that for ethical reasons
the study was not randomized, and this potentially could
influence its results.
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